Bones & Joints
Bones & Joints
Haematologists promote ‘inclusion over exclusion’ for children
Having a bleeding disorder no longer means children will be consigned to watching from the sidelines. Instead, exercise is helping to build physical strength and self-esteem as treatment promotes further inclusion.
Personalised treatment is ‘ultimate aim’ for myeloma researchers
Understanding an individual’s genetic risk profile would see a more tailored approach to treatment, says Myeloma UK’s Director of Research.
How laboratories can benefit from off-the-shelf flow cytometry testing
How off-the-shelf antibody testing has revolutionized flow cytometry testing in the hematology laboratory.
Haematologists are revolutionising how we treat disease
Professor Jo Martin, the President of The Royal College of Pathologists explains how haematologists are revolutionising the way we treat and manage disease through innovations like gene therapy.
CAR-T cell therapy in myeloma: Q&A
What makes CAR-T cell therapy different from current myeloma treatments? ...and other frequently asked questions answered by Dr Rakesh Popat Consultant haematologist at University College Hospital, London.
Understanding and treating blood diseases
From life-long blood disorders like sickle cell disease and hemophilia, to sudden, life-altering blood cancer diagnoses like leukemia or multiple myeloma, blood diseases can be the source of so much uncertainty for patients and their caregivers.
New collaboration to improve outcomes for myeloma patients
Pioneering new myeloma database that measures treatment impact and tracks patient feedback shows how collaboration can mean a win-win for patients, government and industry.
What is flow cytometry?
Flow cytometry plays an integral role in helping doctors to detect diseases like blood cancer, and determine the best treatment pathways. But how does it work?
Complete Blood Count (CBC): at a glance
The complete blood count (CBC) is a test that evaluates the cells that circulate in blood and helps determine your general health status. It may be used to screen for, diagnose, or monitor any one of a variety of diseases and conditions.
Exciting new CAR-T research promises a new therapy for blood cancer
Research collaborations involving industry in CAR-T therapy are providing hope for patients with myeloma.
Myeloma doesn’t stop me leading a great life
"For me, having Myeloma doesn’t mean life stops", says Bob Munro. His story is one of pragmatism, intelligence and a will to contribute to raising Myeloma’s profile.
Balancing innovation and affordability in drug development
The huge advances in treatment for patients with chronic myeloid leukemia has transformed patients’ lives, but the challenge is balancing innovation and affordability.
Global collaboration leads to better healthcare for blood disease patients
Blood diseases exert a huge toll on low- and middle-income countries. By providing local medics with access to global experts, the benefits to patient healthcare can be improved.
Someone is diagnosed with blood cancer every 14 seconds
Blood cancer is the third biggest cancer killer, and yet awareness of the condition remains dangerously low.
A diagnosis of chronic myeloid leukaemia is no longer fatal
Twenty years ago, someone diagnosed with chronic myeloid leukaemia could expect to live just a few years. Now, thanks to huge treatment innovations, many are completely cured.
Why should we connect the entire UK health sector?
There are four big challenges facing our health sector: digital technology, commissioning, procurement and cyber security. But what will it take to get all involved parties working together?
New push to reduce late diagnosis of myeloma
New initiatives aim to increase early diagnosis of myeloma, the little-known blood cancer that claims too many lives.
Using CAR-T cell therapy in blood and other cancer treatments
Trials with chimeric antigen receptors (CARs), which help repair the body’s own immune response, are delivering some ‘remarkable results’ in blood and other cancer treatments.
Tackling the third biggest cancer killer
Few of us realise that blood cancer is the third biggest killer after lung and bowel cancers. Leading charity Bloodwise takes us through the latest advances.
High hopes for new haemophilia treatments
New haemophilia treatments could increase protection, cut complication rates, reduce infusions by half - and save the NHS money.
Why myeloma drug access is currently a ‘lottery’
Empowering GPs to better recognise myeloma risk indicators, and making access to treatment equal, could lead to earlier diagnoses and a better quality of life for patients.
Bones & Joints